Does aprotinin influence the inflammatory response to cardiopulmonary bypass in patients?

Journal of Thoracic and Cardiovascular Surgery

Volumn 125, Issue 1, 2003, Pages 184-190

  Schmartz, Denis ^a   Tabardel, Yves ^a   Preiser, Jean Charles ^a   Barvais, Luc ^a   D'Hollander, Alain ^a   Duchateau, Jean ^b   Vincent, Jean Louis ^a  

^a ERASME HOSPITAL   (Belgium)

^b BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5A; ENDOTOXIN; HISTAMINE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; PREKALLIKREIN; PROSTAGLANDIN D2; TUMOR NECROSIS FACTOR;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; AORTA CLAMPING; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; COMPLEMENT FACTOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 0037245706     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1067/mtc.2003.64     Document Type: Article

References (42)

1. Menasche P. The inflammatory response to cardiopulmonary bypass and its impact on postoperative myocardial function. Curr Opin Cardiol. 199510:597-604.
2. Mojcik CF, Levy JH. Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann Thorac Surg. 2001;71:745-54.
3. Wan S, Leclerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest. 1997;112:676-92.
4. Royston D. Systemic inflammatory responses to surgery with cardiopulmonary bypass. Perfusion. 1996;11:177-89.
5. Tabardel Y, Duchateau J, Schmartz D, Marécaux G, Shahla M, Barvais L, et al. Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men. Surgery. 1996;119:76-80.
6. Hennein HA, Ebba H, Rodriguez JL, Merrick SH, Keith FM, Bronstein MH, et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg. 1994;108:626-35.
7. Engelman RM, Rousou JA, Flack JE, Deaton DW, Kalfin R, Das DK. Influence of steroids on complement and cytokine generation after cardiopulmonary bypass. Ann Thorac Surg. 1995;60:801-4.
8. Bando K, Pillai R, Cameron DE, Brawn JD, Winkelstein JA, Hutchins GM, et al. Leukocyte depletion ameliorates free radical-mediated lung injury after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1990;99:873-7.
9. Baufreton C, Le Besnerais P, Jansen P, Mazzucotelli JP, Wildevuur CR, Loisance DY. Clinical outcome after coronary surgery with heparin-coated extracorporeal circuits for cardiopulmonary bypass. Perfusion. 1996;11:437-43.
10. Wan S, Izzat MB, Lee TW, Wan IY, Tang NL, Yim AP. Avoiding cardiopulmonary bypass in multivessel CABG reduces cytokine response and myocardial injury. Ann Thorac Surg. 1999;68:52-6.
11. Wei M, Kuukasjarvi P, Laurikka J, Kaukinen S, Iisalo P, Laine S, et al. Cytokine responses and myocardial injury in coronary artery bypass grafting. Scand J Clin Lab Invest. 2001;61:161-6.
12. Westaby S. Aprotinin in perspective. Ann Thorac Surg. 1993;55:1033-41.
13. Wachtfogel YT, Kucich U, Hack CE, Niewiarowski S, Colman RW, Edmunds LH Jr. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg. 1993;106:1-9.
14. Siebeck M, Fink E, Weipert J, Jochum M, Fritz H, Spannagl M, et al. Inhibition of plasma kallikrein with aprotinin in porcine endotoxin shock. J Trauma. 1993;34:193-8.
15. Dwenger A, Remmers D, Grotz M, Pape HC, Gruner A, Scharff H, et al. Aprotinin prevents the development of the trauma-induced multiple organ failure in a chronic sheep model. Ear J Clin Chem Clin Biochem. 1996;34:207-14.
16. Royston D. Coagulation in cardiac surgery. Adv Card Surg. 1996;8: 19-45.
17. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung. 1983; 33:479-94.
18. Soeparwata R, Hartman AR, Frerichmann U, Stefano GB, Scheld HH, Bilfinger TV. Aprotinin diminishes inflammatory processes. Int J Cardiol. 1996;53(suppl):S55-63.
19. Gilliland HE, Armstrong MA, Uprichard S, Clarke G, McMurray TJ. The effect of aprotinin on interleukin-8 concentration and leukocyte adhesion molecule expression in an isolated cardiopulmonary bypass system. Anaesthesia. 1999;54:427-33.
20. Ali M, Becket J, Brannan J, Fleming J, Taylor KM. The effect of high dose aprotinin therapy on the systemic inflammatory response in a porcine model of cardiopulmonary bypass. Perfusion. 1996;11:278-80.
21. Hill GE, Alonso A, Spurzem JR, Stammers AH, Robbins RA. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg. 1995; 110:1658-62.
22. Royston D. Preventing the inflammatory response to open-heart surgery: the role of aprotinin and other protease inhibitors. Int J Cardiol. 1996;53(suppl):S11-37.
23. Alonso A, Whitten CW, Hill GE. Pump prime only aprotinin inhibits cardiopulmonary bypass-induced neutrophil CD11b up-regulation. Ann Thorac Surg. 1999;67:392-5.
24. Ashraf S, Tian Y, Cowan D, Nair U, Chatrath R, Saunders NR, et al. "Low-dose" aprotinin modifies hemostasis but not proinflammatory cytokine release. Ann Thorac Surg. 1997;63:68-73.
25. Barvais L. Predictive accuracy of intravenous anesthetic drugs. Acta Anaesthesiol Belg. 1997;48:217-21.
26. Barvais L, D'Hollander AA, Cantraine F, Coussaert E, Diamon G. Predictive accuracy of midazolam in adult patients scheduled for coronary surgery. J Clin Anesth. 1994;6:297-302.
27. Royston D. Aprotinin prevents bleeding and has effects on platelets and fibrinolysis, J Cardiothorac Vasc Anesth. 1991;5:18-23.
28. Richter JA, Meisner H, Tassani P, Barankay A, Dietrich W, Braun SL. Drew-Anderson technique attenuates systemic inflammatory response syndrome and improves respiratory function after coronary artery bypass grafting. Ann Thorac Surg. 2000;69:77-83.
29. Tassani P, Richter JA, Barankay A, Braun SL, Haehnel C, Spaeth P, et al. Does high-dose methylprednisolone in aprotinin-treated patients attenuate the systemic inflammatory response during coronary artery bypass grafting procedures? J Cardiothorac Vasc Anesth. 1999;13:165-72.
30. Appoloni O, Dupont E, Andrien M, Duchateau J, Vincent JL. Association of TNF2, a TNFα promoter polymorphism, with plasma TNFα levels and mortality in septic shock. Am J Med. 2001;110:486-8.
31. Martinez-Pellus AE, Merino P, Bru M, Canovas J, Seller G, Sapina J, et al. Endogenous endotoxemia of intestinal origin during cardiopulmonary bypass. Role of type of flow and protective effect of selective digestive decontamination. Intensive Care Med. 1997;23:1251-7.
32. Ohri SK. Systemic inflammatory response and the splanchnic bed in cardiopulmonary bypass. Perfusion. 1996;11:200-12.
33. Defraigne JO, Pincemail J, Larbuisson R, Blaffart F, Limet R. Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration. Ann Thorac Surg. 2000; 69:1084-91.
34. Hill GE, Pohorecki R, Alonso A, Rennard SI, Robbins RA. Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg. 1996;83:696-700.
35. Gott JP, Cooper WA, Schmidt FE, Brown WM, Wright CE, Merlino JD, et al. Modifying risk for extracorporeal circulation: trial of four antiinflammatory strategies. Ann Thorac Surg. 1998;66:747-53.
36. Dehoux M, Philip I, Chollet-Martin S, Boutten A, Hvass U, Desmonts JM, et al. Early production of interleukin-10 during normothermic cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1995;110:286-7.
37. Hill GE, Diego RP, Stammers AH, Huffman SM, Pohorecki R. Aprotinin enhances the endogenous release of interleukin-10 after cardiac operations. Ann Thorac Surg. 1998;65:66-9.
38. Steinberg JB, Kapelanski DP, Olson JD, Weiler JM. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1993;106:1008-16.
39. Murkin JM. Cardiopulmonary bypass and the inflammatory response: a role for serine protease inhibitors? J Cardiothorac Vasc Anesth. 1997;11:19-23.
40. Royston D. High-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vasc Anesth. 1992;6:76-100.
41. Seghaye MC, Duchateau J, Grabitz RG, Mertes J, Marcus C, Buro K, et al. Histamine liberation related to cardiopulmonary bypass in children: possible relation to transient postoperative arrhythmias. J Thorac Cardiovasc Surg. 1996;111:971-81.
42. Levi-Schaffer F, Shalit M. Differential release of histamine and prostaglandin D2 in rat peritoneal mast cells activated with peptides. Int Arch Allergy Appl Immunol. 1989;90:352-7.